Teva Pharmaceutical Industries (NASDAQ: TEVA): Fourth Quarter Earnings Preview 2009
Wednesday, February 10, 2022 2:33 PM

Related Stories



Teva Pharmaceutical (NASDAQ: TEVA), the world's largest generic drugmaker, is scheduled to release its fiscal fourth-quarter 2009 financial results on Tuesday, February 16, 2009. Analysts, on average, expect the company to report earnings of 95 cents a share on revenue of $3.81 billion. In the year ago period, the company posted earnings of 76 cents per share on revenue of $2.85 billion.

Teva Pharmaceutical Industries Limited engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide. Its research and development efforts focus on therapies for the central nervous system (with emphasis on multiple sclerosis), autoimmune diseases, and oncology.

Early in November, the Petach Tikva, Israel-based company reported that its third quarter net income $649 million, up from $631 million in the year-ago quarter. However, per share earnings dropped to $0.72 from $0.77 reported in the same quarter of last year. On a non-GAAP basis, net income attributable to Teva advanced 28% to $806 million, from $630 million in the prior-year quarter. Non-GAAP earnings per share grew 16% to $0.89 from $0.77 in the comparable quarter of the previous year. Revenue totaled $3.55 billion, 25% higher than the previous year's net sales of $2.84 billion. Analysts, on average, expected the company to post earnings of $0.88 per share on revenue of $3.63 billion. In the quarter, GAAP gross profit margin rose to 54.3% from 52.5% a year ago.

Global in-market sales of Teva's flagship product Copaxone- the world's leading therapy for the treatment of multiple sclerosis, was $776 million, up 38% year-over-year. In the U.S., in-market sales climbed 53% to reach $540 million from 2008. In-market sales outside the U.S. totaled $236 million, up 12% year-over-year. In local currencies, in-market sales of Copaxone outside the U.S. grew 23%.

Teva expects to double revenues by 2015, anticipating robust growth in its core generic business. For 2015, the Israel-based company plans to achieve revenue of $31 billion, and non-GAAP net income of $6.8 billion. It expects the growing worldwide demand for generic drugs to boost the growth of its core business in the U.S., as well as globally. A significant portion of the growth is expected to come from those European and international markets that are currently characterized by low generic penetration rates. It intends to strengthen its branded business further through internal R&D, licensing and other business development opportunities, and geographic expansion of its existing product portfolio. The company is also focusing on Biogenerics, which is another important growth driver, and has indicated taking significant steps to build the necessary infrastructure to accomplish its goal as a market leader in this field. Teva hopes to exceed market growth by its market leadership and competitive advantages, its high degree of back integration, the robustness of its product portfolio and track record in being first to market in the U.S. and other regions and its commitment to high quality.

Early this month, the pharmaceutical company stated that several of its US subsidiaries reached a settlement in principle to resolve claims brought by Ven-A-Care of the Florida Keys, Inc. on behalf of the United States, Texas, Florida, and California under federal and state False Claims Acts. As a result, Teva will record a charge of around $315 million in its fourth quarter results.

In December, Teva Pharmaceutical Industries and OncoGenex Pharmaceuticals (NASDAQ: OGXI) entered into a global license and collaboration agreement to develop and commercialize cancer drug candidate OGX-011. Moshe Manor, Teva's Group vice president, Global Branded Products, said, "We see OGX-011 as a key component of our branded oncology medicines franchise, expanding our pipeline of existing oncology therapeutics and broadening the future available therapies made by Teva for oncology patients and care providers."

Teva estimates that the agreement will further enhance its oncology offerings and strengthen its global branded product pipeline with a promising product candidate entering three Phase III trials involving large patient populations.

In January, the company said that the FDA has granted tentative approval for its abbreviated new drug application to market its generic version of Novartis' breast cancer treatment Femara Tablets, 2.5 mg.  In November, the generic-drug maker said that the U.S. Food and Drug Administration granted it final approval to market the generic version of Tap Pharmaceutical's proton pump inhibitor Prevacid.

The company's stock currently trades at a forward P/E (fye 31-Dec-10) of 12.64 and PEG Ratio (5 yr expected) of 1.11. In terms of stock performance, Teva shares have gained 34 percent over the past year.

Disclosure: Author doesn't own any of the stocks discussed here.

 

Sponsors

Symbol :

Advertisement

Market news:

  • US shoppers crowd malls all night long Nov 26, 2021 07:09 AM

    • Bargain shoppers, braving rain or frigid weather, crowded the nation's stores and malls in the wee hours of the night to get their hands on deals from TVs to toys on Black Friday.
    • In a bid to grab shoppers earlier on the traditional start to the holiday shopping season, a number of stores including Old Navy, Toys R Us and Sears opened on Thursday's Thanksgiving holiday.
    • Patricia Lopez, 32, a receptionist from Queens, N.Y., was in line at Toys R Us in New York's Times Square Thursday night.
      • NKorea warns region is on brink of war Nov 26, 2021 06:53 AM

        • YEONPYEONG ISLAND, South Korea - North Korea warned Friday that U.S.-South Korean plans for military maneuvers put the peninsula on the brink of war, and appeared to launch its own artillery drills within sight of an island it showered with a deadly barrage this week.
        • The fresh artillery blasts were especially defiant because they came as the U.S. commander in South Korea, Gen. Walter Sharp, toured the South Korean island to survey damage from Tuesday's hail of North Korean artillery fire that killed four people.
        • None of the latest rounds hit the South's territory, and U.S. military officials said Sharp did not even hear the concussions, though residents on other parts of the island panicked and ran back to the air raid shelters where they huddled earlier in the week as white smoke rose from North Korean territory.
          • Teenagers adrift in Pacific for 50 days reach land Nov 26, 2021 06:26 AM

            • SUVA, Fiji - Three teenage boys who spent 50 days adrift in a tiny boat in the South Pacific walked ashore on shaky legs Friday after their chance rescue - celebrated on their home island hundreds of miles (kilometers) away as a miracle that brought them back from the dead.
            • The trio - Samuel Pelesa and Filo Filo, both 15, and Edward Nasau, 14 - told rescuers they survived on rainwater they collected, a handful of coconuts, raw fish and a seagull that landed on their 12-foot- (3.5-meter-) long aluminum boat.
            • The boys set off Oct. 5 from their home island to one nearby.
              • Roll Tide! War Eagle! Alabama-Auburn stands apart Nov 26, 2021 05:57 AM

                • TUSCALOOSA, Ala. - They start early in this part of the country.
                • "You got to declare when you're a youngster," said Gene Stallings, the former Alabama coach.
                • "I'm prejudiced," said Pat Dye, who coached at Auburn for a dozen years, "but I don't think there's any other game in the country that's talked about on a daily basis as much as this one is by the folks in the state of Alabama."
                  • Black Friday shoppers crowd malls all night long Nov 26, 2021 05:55 AM

                    • After weeks of "Black Friday" sales pitches, the real thing is finally here.
                    • Many stores had trotted out the "Black Friday" label on sales as far back as October.
                    • In a bid to grab shoppers earlier, a number of stores including Old Navy, Toys R Us and Sears opened on Thanksgiving Day.

                      More news


Advertisement

    Recent Estimates

AnalystFirm NameSymbolEPS Estimate
GEOXXXXX PAY$0.31
mrbilltraderXXXXX POT$1.15
XXXXXXXXXX OVTI$0.43
sam farahanXXXXX TECD$0.95
XXXXXXXXXX GSS$0.05
XXXXXXXXXX ABB$0.31
adfgafg ERTS($0.26)
XXXXXXXXXX SD$0.03
XXXXXXXXXX ATML$0.11
XXXXXXXXXX CBPO$0.32